Aggregation, immune complexes and immunogenicity

mAbs

Volumn 3, Issue 6, 2011, Pages 503-504

  Jefferis, Roy ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; DRUG MEGADOSE; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PROTEIN PROCESSING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; MICE;

EID: 81255176906     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.6.17611     Document Type: Editorial

References (21)

1. Rosenberg AS. Effects of protein aggregation: an immunologic perspective. AAPS J 2006; 8:501-7.
2. Büttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R. et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 2011; 3:100-9.
3. van Beers MM, Jiskoot W, Schellekens H. On the role of aggregates in the immunogenicity of recombinant interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res 2010; 30:767-75.
4. Mitchison NA. Induction of immunological paralysis in two zones of dosage. Proc R Soc Lond B Biol Sci 1964; 161:275-92.
5. Somerfield J, Hill-Cawthorne GA, Lin A, Zandi MS, McCarthy C, Jones JL, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol 2010; 185:763-8.
6. Enhanced production of antibodies utilizing insolubilized immune complexes. United States Patent 5084396.
7. Abdel-Motal UM, Wigglesworth K, Galili U. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with natural anti-Gal antibody. Vaccine 2009; 27:3072-82.
8. Ostreiko KK, Tumanova IA, Sykulev YuK. Production and characterization of heat-aggregated IgG complexes with pre-determined molecular masses: light-scattering study. Immunol Lett 1987; 15:311-6. (Pubitemid 17126880)
9. Zhang W, Voice J, Lachmann PJ. A systematic study of neutrophil degranulation and respiratory burst in vitro be defined immune complexes. Clin Exp Immunol 1995; 101:507-14.
10. Voice JK, Lachmann PJ. Neutrophil Fcgamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble immune complexes. Eur J Immunol 1997; 27:2514-23. (Pubitemid 27453838)
11. Steensgaard J, Frich JR. A theoretical approach to precipitin reactions: Insight from computer simulation. Immunol 1979; 36:279-91. (Pubitemid 10220714)
12. Steensgaard J, Jacobsen C, Lowe J, Ling NR, Jefferis R. Theoretical and ultracentrifugal analysis of immune complex formation between monoclonal antibodies and human IgG. Immunol 1982; 46:751-60. (Pubitemid 12038350)
13. Jefferis R, Deverill I, Steensgaard J. Characteristics of monoclonal antibody interactions and their application to quantitative techniques. Biochem Soc Trans 1981; 9:116-7.
14. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti0CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosomae-mediated cell death in B-cell malignancies. Blood 2011; 117:4519-29.
15. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M. Epitope characterisation and crystal structure of GA101 provides insights into the molecular basis for type I/II distinctions of CD20 antibodies. Blood 2011; 118:358-67.
16. Kim MS, Lee SH, Song MY, Yoo TH, Lee BK, Kim YS. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol 2007; 374:1374-88. (Pubitemid 350122551)
17. Padlan EA. X-ray crystallography of antibodies. Adv Protein Chem 1996; 49:57-133. (Pubitemid 26360375)
18. Guo D, Gao A, Michels DA, Feeney L, Eng M, Chan B, et al. Mechanisms of unintended amino acid sequence changes in recombinant monoclonal antibodies expressed in Chinese Hamster Ovary (CHO) cells. Biotechnol Bioeng 2010; 107:163-71.
19. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2010; 2:613-24.
20. Hale G, Rebello P, Al Bakir I, Bolam E, Wiczling P, Jusko WJ. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol 2010; 50:1238-48.
21. Pan J, Small T, Qin D, Li S, Wang L, Chen D, et al. Comparison of the NIDS rapid assay with ELISA methods in immunogenicity of two biotherapeutics J. Pharmacol Toxicol Methods 2011; 63:150-9.